<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3536">
  <stage>Registered</stage>
  <submitdate>26/04/2012</submitdate>
  <approvaldate>26/04/2012</approvaldate>
  <nctid>NCT01589549</nctid>
  <trial_identification>
    <studytitle>Mesenchymal Stromal Cells for Acute Graft Versus Host Disease</studytitle>
    <scientifictitle>A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CTN 2012/0174</secondaryid>
    <secondaryid>2011/128</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute GVH Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Mesenchymal stromal cell therapy

Experimental: Mesenchymal stromal cell therapy - Mesenchymal stromal cell therapy in addition to corticosteroid therapy

Active Comparator: Corticosteroid therapy - 


Other interventions: Mesenchymal stromal cell therapy
One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival at one year after onset of graft versus host disease</outcome>
      <timepoint>One year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Response at 14 days after commencement of treatment for acute graft versus host disease</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response at 28 days after commencement of treatment of acute graft versus host disease</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of severe infection</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease free survival at one year</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to treatment failure, requiring salvage therapy</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Grades 2-4 acute graft versus host disease after bone marrow transplantation up to day
             +180 after transplantation

          -  Age 18-55 years

               -  Must be receiving a calcineurin inhibitor</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Failure to sign informed consent

          -  Corticosteroid therapy for 72 hours or greater

          -  ECOG score equal to or greater than 3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>R.P.Herrmann</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Perth Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomised study of corticosteroid therapy with or without mesenchymal stromal cell therapy
      for newly diagnosed acute graft versus host disease after bone marrow transplantation or
      donor lymphocyte therapy.

      It is hypothesised that mesenchymal stromal cell therapy will be superior</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01589549</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Duncan Purtill, MB, BS</name>
      <address>Royal Perth Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Duncan Purtill, MB, BS</name>
      <address />
      <phone>+61 8 61523788</phone>
      <fax />
      <email>duncan.purtill@health.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>